$CYDY CytoDyn Inc. (CYDY) CytoDyn Inc. is a Van
Post# of 2218
CytoDyn Inc. is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn's lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection.